Skip to search formSkip to main contentSkip to account menu

SEN0014196

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
A randomized, double-blind, placebo-controlled phase Ib study with selisistat (SEN0014196) in patients with Huntington's disease
2012
2012
FROM BIOLOGY TO THE BEDSIDE-SIRTUINS AS TARGETS FOR DISEASE MODIFICATION IN HUNTINGTON'S DISEASE: SELISISTAT PRECLINICAL DATA AND PRELIMINARY PHASE I RESULTS
To date no disease modifying therapy has shown efficacy in Huntington's Disease (HD). The PADDINGTON (Pharmacodynamic Approaches… 
2012
2012
F04 Selisistat: potential pharmacodynamic readouts based on transcriptomics
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selisistat… 
2012
2012
F02 Selisistat: soluble HTT protein levels as a potential pharmacodynamic readout
Background Siena Biotech SpA is developing selisistat (SEN0014196) as a potentially disease-modifying therapy for HD. Selsistat… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)